Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Aldehyde dehydrogenase inhibitor (alcohol-aversion therapy for alcohol use disorder)

Disulfiram

Antabuse (compounded; not commercially marketed in Canada)

Dosage form
Tablet
Available strengths
125 mg, 250 mg, 500 mg (compounded)
Drug class
Aldehyde dehydrogenase inhibitor (alcohol-aversion therapy for alcohol use disorder)
Common brand
Antabuse (compounded; not commercially marketed in Canada)

Clinical overview. Disulfiram is an aversive therapy for alcohol use disorder that irreversibly inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate and produce an extremely unpleasant, potentially dangerous reaction (flushing, nausea, vomiting, palpitations, hypotension) if the patient drinks alcohol. It is a second-line AUD medication, most effective under supervised/witnessed daily administration, and is not currently commercially available in Canada -- it must be compounded by a specialty pharmacy.

Indication

Common therapeutic uses

  • Second-line pharmacotherapy for alcohol use disorder in a motivated patient pursuing abstinence, used after (or instead of, when strongly preferred) naltrexone and acamprosate.
  • Most effective when administration is supervised or witnessed (e.g., daily observed dosing by a partner, pharmacist, or care team member).

Pregnancy

Risk assessment and monitoring considerations

  • Safety in pregnancy has not been established; avoid unless the potential benefit clearly outweighs the risk, given the severity of the disulfiram-alcohol reaction and limited safety data.

Breastfeeding

Infant exposure considerations

  • Not recommended during breastfeeding; safety data in lactation are lacking.

Geriatrics

Dosing and tolerability considerations

  • Use with caution given increased likelihood of hepatic impairment and comorbid cardiovascular disease, both of which increase risk with this medication; consider the lower 125 mg starting dose.

Pediatrics

Use in children and adolescents

  • Not established for pediatric use.

Dosage & Administration

Practical dosing and administration

  • Usual dose: 250 mg PO once daily, taken in the morning or evening depending on tolerability of sedation.
  • Alternative dose: 125 mg PO once daily if daytime sedation persists at 250 mg, or as a lower initial dose.
  • Maximum dose: 500 mg PO once daily — do not exceed, and only used if a patient can drink alcohol without a reaction at 250 mg despite confirmed adherence (very rare).
  • Patients must abstain from alcohol for at least 24-48 hours before the first dose. Because disulfiram irreversibly inhibits aldehyde dehydrogenase, the disulfiram-alcohol reaction risk can persist for up to 2 weeks after the last dose, since enzyme activity only recovers as new enzyme is synthesized.
  • Full, informed patient (and, where relevant, family/support person) consent and counselling on the disulfiram-alcohol reaction must be completed before the first dose.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Disulfiram overdose without concurrent alcohol is generally low-toxicity but can cause drowsiness and GI upset; the principal danger is a severe disulfiram-alcohol reaction if alcohol (including non-beverage/incidental alcohol exposure) is consumed, which can include marked hypotension, arrhythmias, and rarely death — this is a medical emergency requiring supportive care.

Common side effects

Frequently reported tolerability concerns

  • In the absence of alcohol: drowsiness, fatigue, headache, and a metallic or garlic-like aftertaste.
  • Skin eruptions (acne-like or dermatitis) may occur.
  • Erectile dysfunction has been reported.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Hepatotoxicity, including rare cholestatic or fulminant hepatitis and hepatic failure requiring transplantation or resulting in death, can occur with or without a prior history of abnormal liver function — obtain baseline and periodic liver function tests.
  • The disulfiram-alcohol reaction itself: flushing, throbbing headache, nausea, vomiting, sweating, chest pain, palpitations, dyspnea, hypotension, and, rarely, cardiovascular collapse, arrhythmia, or death. Severity generally relates to both the disulfiram dose and the amount of alcohol consumed.
  • Rare psychotic reactions have been reported.
  • Peripheral neuropathy has been reported rarely with prolonged use.

Use with caution

Situations requiring closer assessment

  • Use with caution in diabetes mellitus, hypothyroidism, seizure disorders, cerebral damage, chronic or acute nephritis, an abnormal EEG, or a co-occurring substance use disorder.
  • Use with caution in significant cardiovascular disease given the cardiovascular effects of a disulfiram-alcohol reaction if exposure occurs.

Contraindications

Situations where therapy may be inappropriate

  • Known hypersensitivity to disulfiram or to other thiuram (rubber) derivatives.
  • Current alcohol intoxication.
  • Concurrent or recent use of alcohol, alcohol-containing preparations, or metronidazole (avoid metronidazole within 2 weeks of disulfiram use).
  • Severe myocardial disease or coronary occlusion.
  • Active psychosis.

Drug interactions

Clinically relevant combinations

  • Metronidazole is contraindicated within 2 weeks of disulfiram use because of an increased risk of psychosis and confusion.
  • Increases serum concentration of phenytoin; avoid combining if possible, or monitor phenytoin levels closely.
  • Can increase the effect of warfarin and other oral anticoagulants; monitor INR more closely after starting or stopping disulfiram.
  • Acetaldehyde accumulation and a disulfiram-like reaction can occur with paraldehyde and with certain alcohol-containing prescription liquid formulations (e.g., some lopinavir/ritonavir, sertraline oral solution, tipranavir, and carbocisteine products).
  • Over-the-counter products with meaningful alcohol content (cough and cold syrups, mouthwash, some topical/liniment products) can trigger a reaction and should be avoided.

Food interactions

Meal-related administration

  • Avoid all alcohol, including alcohol used in cooking (the reaction can be triggered by even modest amounts) and sauces or vinegars prepared without full evaporation of their alcohol content.

Time of administration

Practical scheduling

  • Taken once daily, in the morning or evening; evening dosing can reduce daytime sedation.

Storage

Product handling

  • Store at room temperature (15-30°C), away from moisture, out of reach of children.

Patient take-away

Key counselling points for a quick closing summary

  • Disulfiram causes a severe, unpleasant, and potentially dangerous reaction — flushing, throbbing headache, nausea, vomiting, and a racing heart — if you drink any alcohol while taking it, or for up to 2 weeks after your last dose.
  • Avoid all sources of alcohol, including cough syrups, mouthwash, cooking wine or sauces, and alcohol-based products used near your mouth or nose.
  • Take your dose at the same time every day; taking it in the evening can help if it makes you drowsy.
  • Contact your healthcare team immediately for yellowing of the skin or eyes, dark urine, severe fatigue, or loss of appetite — these can be early signs of liver injury.
  • If you accidentally consume alcohol and develop chest pain, severe shortness of breath, fainting, or a very fast or irregular heartbeat, seek emergency care immediately.
  • This medication is not sold commercially in Canada and must be specially prepared (compounded) by your pharmacy — plan ahead with your pharmacist to make sure it is available when you need a refill.

References

Source material and product information

  1. DailyMed official Disulfiram (Antabuse) product labelling

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.